Immune checkpoint proteins are proteins expressed in immune cells and can maintain immune homeostasis. Their abnormal expression and functional imbalance lead to various diseases, such as tumors and autoimmunity. In recent years, the successive marketing of antibody drugs developed for immune checkpoints, such as PD-1/PD-L1 and CTL-4, has opened the door to immunotherapy. Clinical trials on popular targets such as CD24, B7-H3, and 4-1BB are also in full swing, and new immune checkpoints such as CD161 and TREAM2 have also provided new ideas for immunotherapy.
